Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Resistant Hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    93 result(s) found for: Resistant Hypertension. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2019-002334-36 Sponsor Protocol Number: 2018/350/HP Start Date*: 2021-12-02
    Sponsor Name:CHU de Rouen
    Full Title: VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
    Medical condition: Resistant arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038466 Renal hypertension and related conditions HLT
    20.0 100000004866 10038465 Renal hypertensions HLT
    21.1 10038359 - Renal and urinary disorders 10038464 Renal hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001890-42 Sponsor Protocol Number: CLHW090X2202 Start Date*: 2016-04-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, sponsor open, site and subject double-blind, parallel group, placebo-controlled study to evaluate the safety and efficacy of LHW090 after 4 weeks treatment in patients with resistant ...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10015491 Essential hypertension, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) DK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002681-63 Sponsor Protocol Number: 2007CV04 Start Date*: 2008-08-28
    Sponsor Name:Research and Innovation Services, University of Dundee
    Full Title: DOES VITAMIN D REDUCE BLOOD PRESSURE AND LV MASS IN RESISTANT HYPERTENSIVE PATIENTS WITH VITAMIN D INSUFFICIENCY?
    Medical condition: Resistant Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020783 Hypertension not adequately controlled LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001998-25 Sponsor Protocol Number: BLO K025 Start Date*: 2006-09-29
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous...
    Medical condition: Insulin-resistant obese patients with a hypertension not adequately controlled by previous beta-blocker or calcium channel blocker
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001404-14 Sponsor Protocol Number: QGC001-3QG2 Start Date*: 2021-08-17
    Sponsor Name:Quantum Genomics
    Full Title: A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-...
    Medical condition: Treatment of patients with difficult-to-treat and/or treatment-resistant hypertension (HTN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10036695 Primary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) HU (Prematurely Ended) ES (Ongoing) CZ (Prematurely Ended) IT (Completed) NL (Prematurely Ended) BE (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003558-27 Sponsor Protocol Number: ASPIRANT Start Date*: 2007-07-30
    Sponsor Name:Olomouc University Hospital and Palacký University School of Medicine, Internal Medicine Dept. I
    Full Title: Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)
    Medical condition: arterial hypertension resistant to treatment (target blood pressure not reached with a combination of at least three different antihypertensive drugs, one of them being a diuretic)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020783 Hypertension not adequately controlled LLT
    9.1 10020775 Hypertension arterial LLT
    9.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007338-23 Sponsor Protocol Number: CLCI699A2216 Start Date*: 2009-02-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks...
    Medical condition: resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2006-004846-17 Sponsor Protocol Number: STH 14399 Start Date*: 2007-03-16
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A randomised, placebo controlled trial of the efficacy of the addition of spironolactone to modern antihypertensive treatment regimes in patients with resistant hypertension.
    Medical condition: Resistant hypertension.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007149-30 Sponsor Protocol Number: 4500 Start Date*: 2009-01-14
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge [...]
    1. Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    2. Cambridge Clinical Trials Unit
    Full Title: Optimal Treatment of Drug Resistant Hypertension
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    15.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004995-13 Sponsor Protocol Number: 38372 Start Date*: 2012-02-09
    Sponsor Name:Erasmus MC
    Full Title: Endovascular renal sympathetic denervation versus spironolactone for treatment-resistant hypertension: a randomized, multicentric study
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001004-39 Sponsor Protocol Number: JO-3 Start Date*: 2005-07-05
    Sponsor Name:University of Edinburgh
    Full Title: Investigation of combined phosphodiesterase 5 inhibitor and isosorbide mononitrate for the treatment of resistant hypertension
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001898-25 Sponsor Protocol Number: DAR-311 Start Date*: 2006-09-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Effica...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000874-19 Sponsor Protocol Number: 1235.21 Start Date*: 2008-11-19
    Sponsor Name:Boehringer Ingelheim Pharmaceuticals. Inc.
    Full Title: A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg...
    Medical condition: type 2 diabetes and mild to moderate hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000785-35 Sponsor Protocol Number: PAIR Start Date*: 2011-04-13
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE STUDY TO ASSESS THE INTERACTION BETWEEN PATIENT GENOTYPE AND ROSTAFUROXIN EFFECTS ON ARTERIAL BLOOD PRESSURE AND KIDNEY FUNCTION IN NEVER-TREATED HYPERTENSIVE TYPE 2 DIABETES PATIENT...
    Medical condition: Type 2 Diabetes.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10015491 Essential hypertension, unspecified LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012612 Diabetes mellitus non insulin-dep LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001899-20 Sponsor Protocol Number: DAR-311-E Start Date*: 2007-01-16
    Sponsor Name:Gilead Sciences Inc.
    Full Title: DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension A Dose-Blinded, Long-Term Safety Extension Study...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) SE (Prematurely Ended) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006436-22 Sponsor Protocol Number: BAY a 1040 - BAY 68-9291/12313 Start Date*: 2007-08-29
    Sponsor Name:BAYER
    Full Title: A multicenter Study Evaluating the Efficacy of Nifedipine GITS ﾖ Telmisartan Combination in Blood Pressure Control and Beyond: comparison of two strategies.
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    6.1 10020772 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002657-38 Sponsor Protocol Number: RLY5016-207 Start Date*: 2017-01-09
    Sponsor Name:Relypsa, Inc
    Full Title: A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chr...
    Medical condition: Resistant Hypertension and Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-007749-29 Sponsor Protocol Number: UKCRN4499 Start Date*: 2009-09-02
    Sponsor Name:R&D Department, [...]
    1. R&D Department,
    2. Cambridge Clinical Trials Unit
    Full Title: Monotherapy vs Dual Therapy for Initial Treatment for hypertension
    Medical condition: Resistant Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003548-42 Sponsor Protocol Number: DAR-312-E Start Date*: 2008-04-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension A Double-Blind, Active-...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) BE (Completed) FR (Completed) DE (Prematurely Ended) ES (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003547-23 Sponsor Protocol Number: DAR-312 Start Date*: 2007-11-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Grou...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) BE (Completed) DK (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:20:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA